The interview with Michel Verhasselt about the reimbursement of medical devices in Belgium

20

Jan 2020

We have released the interview on the Market Access Insider channel on Youtube. Michel Verhasselt is the Founder and CEO of Meditech Access SAS.

The interview covered key stakeholders, reimbursement mechanism and pathways for procedures, implantable and invasive devices, coverage with evidence development program in Belgium. Michel shared a lot of first-hand insights from the reimbursement submissions in the country.

Watch the interview here.

The latest related news

15

Mar 2022

The Belgian Health Care Knowledge Center (KCE) initiated a study aimed at defining a clear and transparent procedure for the evaluation of digital health technologies in Belgium.

Read more

02

Mar 2022

A new temporary reimbursement framework for remote consultations is planned to be implemented in Belgium in spring 2022.

Read more

17

Feb 2022

Since 2019, several low-cost and simple procedures in Belgium have been reimbursed not via individual INAMI fees but APR-DRG groups. This funding system is called “Low Variability Care”. On January 26, 2022, the list of APR-DRG groups and corresponding reimbursement amounts for 2022 was published.

Read more

01

Feb 2022

At the beginning of January 2022, the INAMI published a convention for 2022-2023 related to the financing of dialysis. The convention regulates the modalities of reimbursement for dialysis of patients with chronic renal failure.

Read more

27

Jan 2022

On December 17, 2021, the Belgian Health Care Knowledge Center (KCE) published a health services research report “Evidence gaps for drugs and medical devices at market entry in Europe and potential solutions”. In this report, KCE examined the lack of comparative evidence health technology assessment (HTA) agencies and payers face in evaluating new medicinal products and high-risk medical devices at market entry.

Read more